Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
IcsResultsAssociations of DC-SCRIPT with clinicopathological factors and histological and intrinsic breast cancer subtypesThe relationship between DC-SCRIPT and patient and tumor characteristics was investigated with the use of non-parametric methods (Spearman rank correlations for continuous variables and Wilcoxon rank-sum for dichotomized or Kruskal-Wallis test for ordered variables). To reduce
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
Mors. Quantitative polymerase chain reaction cut points are shown for high versus low DC-SCRIPT (66.7 versus 33.3 ) [7], for positive versus negative ESR1 (0.2) [14], and for ESR2-low versus -high at the median level of 0.005 (mRNA levels relative to reference gene set). Patients at risk are indicated. DCSCRIPT, dendritic cell-specific transcript; ESR, estrogen receptor; pT1, small tumor without
Mors. Quantitative polymerase chain reaction cut points are shown for high versus low DC-SCRIPT (66.7 versus 33.3 ) [7], for positive versus negative ESR1 (0.2) [14], and for ESR2-low versus -high at the median level of 0.005 (mRNA levels relative to reference gene set). Patients at risk are indicated. DCSCRIPT, dendritic cell-specific transcript; ESR, estrogen receptor; pT1, small tumor without